According to specialists from the National Cancer Institute, the latest changes in drug reimbursement for oncology patients touch on several important aspects, but first and foremost are signals that the gap between the availability of modern therapies in Poland and other European countries is narrowing.
The new reimbursement list includes preparations for relatively common oncological diseases, such as second-line treatment of patients with ovarian cancer and therapies for rare oncological diseases. Here, an example is acalabrutinib used for chronic lymphocytic leukemia patients with a specific biological subtype of the disease - In rare oncological diseases, establishing a cost-effectiveness threshold is usually very difficult, and the process of determining the ava... To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].Content locked
